Aurinia Pharmaceuticals Inc. (AUPH)

USD 9.1

(-4.71%)

Market Cap (In USD)

1.3 Billion

Revenue (In USD)

175.51 Million

Net Income (In USD)

-78.02 Million

Avg. Volume

1.43 Million

Currency
USD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
4.71-10.67
PE
-
EPS
-
Beta Value
1.456
ISIN
CA05156V1022
CUSIP
05156V102
CIK
1600620
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Mr. Peter S. Greenleaf M.B.A.
Employee Count
-
Website
https://www.auriniapharma.com
Ipo Date
2014-09-03
Details
Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States and internationally. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company is headquartered in Victoria, Canada.